Agatha Meeks Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 12829 N 113th Ave Apt 2, Youngtown, AZ 85363 Phone: 623-329-4652 |
Dr. Denita Manning, LPCC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 12600 N 113th Ave Ste B9, Youngtown, AZ 85363 Phone: 602-845-0767 |
Dr. Mancy Howard Jr., LPCC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 12600 N 113th Ave Ste B9, Youngtown, AZ 85363 Phone: 602-845-0767 Fax: 602-715-0647 |
Dr. Andre E Matthews, LPCC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 12600 N 113th Ave Ste B8, Youngtown, AZ 85363 Phone: 602-845-0767 |
Michelle Hutchison, M.C., LPC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 12600 N 113th Ave, Suite B-9, Youngtown, AZ 85363 Phone: 623-330-9035 |
Karen L Brozik, MA, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 12600 N 113th Ave, Suite C-19, Youngtown, AZ 85363 Phone: 928-617-0077 |
News Archive
New Haven, Conn.-Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases.
Vitamin E supplements do not protect healthy women against heart attacks and stroke, according to new results from the Women's Health Study, a long-term clinical trial of the effect of vitamin E and aspirin on both the prevention of cardiovascular disease and of cancer.
"Most people focus on the dislike of the preparation, the need to arrange transportation and the fear of being anesthetized during the procedure and then potentially getting a cancer diagnosis," says Neil Gupta, MD, MPH, Director of Endoscopy at Loyola University Health System. "Screening colonoscopy is a very critical examination that really can determine life and death when it comes to colon cancer. It is now clear that not every colonoscopy is equal. Once you've decided it's time to get a screening colonoscopy, the next step is to make sure that you get a high-quality one."
Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, today announces its partner Allergan, Inc has initiated two Phase II trials to evaluate the safety and efficacy of its re-targeted endopeptidase drug candidate AGN-214868. The Phase II trials will be focused on patients with post herpetic neuralgia (PHN) and overactive bladder.
› Verified 6 days ago